Pharmacologic treatments for pulmonary hypertension: Exploring pharmacogenomics

Future Cardiology

Volumn 9, Issue 3, 2013, Pages 335-349

  Duarte, Julio D ^a   Hanson, Rebekah L ^a   Machado, Roberto F ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

endothelin receptor antagonist; pharmacogenetics; pharmacogenomics; phosphodiesterase type 5 inhibitor; prostacyclin analog; pulmonary hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; CARBAMAZEPINE; CYCLIC GMP; CYCLOSPORIN A; CYTOCHROME P450; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; GLIBENCLAMIDE; ILOPROST; KETOCONAZOLE; NITRATE; NITRIC OXIDE; PHENYTOIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN RECEPTOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; TEZOSETAN; TREPROSTINIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART FAILURE; ACUTE RESPIRATORY FAILURE; ANEMIA; AREA UNDER THE CURVE; ARTERY DILATATION; BACTEREMIA; BIRTH DEFECT; CARDIOVASCULAR RISK; CATHETER COMPLICATION; CATHETER THROMBOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DYSPEPSIA; EARLY TERMINATION OF CLINICAL TRIAL; EXERCISE TEST; EXERCISE TOLERANCE; FLUSHING; FOOD; FOOD DRUG INTERACTION; HEADACHE; HEART AFTERLOAD; HEART FAILURE; HEART INFARCTION; HEART OUTPUT; HUMAN; HYPOTENSION; INJECTION SITE PAIN; ISCHEMIC OPTIC NEUROPATHY; JAW PAIN; LEG PAIN; LIPID DIET; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUNG GAS EXCHANGE; LUNG VASCULAR RESISTANCE; NAUSEA; NOSE OBSTRUCTION; PAIN; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RECEPTOR GENE; RECOMMENDED DRUG DOSE; RETINA DISEASE; REVIEW; SIDE EFFECT; SINUSITIS; THROAT IRRITATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VISUAL IMPAIRMENT; WALKING;

HUMANS; HYPERTENSION, PULMONARY; PHARMACOGENETICS;

EID: 84877844480     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.6     Document Type: Review

References (166)

1. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur. Respir. J. 30(6), 1103-1110 (2007).
2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGgoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142(2), 448-456 (2012).
3. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S43-S54 (2009).
4. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006).
5. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 30(1), 104-109 (2007).
6. Machado RD, Aldred MA, James V et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. 27(2), 121-132 (2006).
7. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N. Engl. J. Med. 361(19), 1864-1871 (2009).
8. Cogan J, Austin E, Hedges L et al. Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance. Circulation 126(15), 1907-1916 (2012).
9. Trembath RC, Thomson JR, Machado RD et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 345(5), 325-334 (2001).
10. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333(4), 214-221 (1995).
11. Rubens C, Ewert R, Halank M et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120(5), 1562-1569 (2001).
12. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J. Am. Coll. Cardiol. 59(5), 442-451 (2012).
13. Ghio S, Gavazzi A, Campana C et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J. Am. Coll. Cardiol. 37(1), 183-188 (2001).
14. Willens HJ, Kessler KM. Severe pulmonary hypertension associated with diastolic left ventricular dysfunction. Chest 103(6), 1877-1883 (1993).
15. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J. Am. Coll. Cardiol. 53(13), 1119-1126 (2009).
16. Bursi F, Mcnallan SM, Redfield MM et al. Pulmonary pressures and death in heart failure: a community study. J. Am. Coll. Cardiol. 59(3), 222-231 (2012).
17. Oswald-Mammosser M, Weitzenblum E, Quoix E et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 107(5), 1193-1198 (1995).
18. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129(3), 746-752 (2006).
19. Hoeper MM, Barbera JA, Channick RN et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S85-S96 (2009).
20. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350(22), 2257-2264 (2004).
21. Condliffe R, Kiely DG, Gibbs JS et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 177(10), 1122-1127 (2008).
22. Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr. Opin. Pulm. Med. 13(5), 434-438 (2007).
23. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 183(5), 573-581 (2011).
24. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 130(5), 1481-1488 (2006).
25. Barnett CF, Bonura EJ, Nathan SD et al. Treatment of sarcoidosis- associated pulmonary hypertension. A two-center experience. Chest 135(6), 1455-1461 (2009).
26. Macchia A, Marchioli R, Tognoni G et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am. Heart J. 159(2), 245-257 (2010).
27. Savarese G, Paolillo S, Costanzo P et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J. Am. Coll. Cardiol. 60(13), 1192-1201 (2012).
28. Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? Am. J. Respir. Crit. Care Med. 186(5), 396-397 (2012).
29. Rich S. The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension. J. Am. Coll. Cardiol. 60(13), 1202-1203 (2012).
30. Said SI, Hamidi SA. Pharmacogenomics in pulmonary arterial hypertension: toward a mechanistic, target-based approach to therapy. Pulm. Circ. 1(3), 383-388 (2011).
31. Geraci MW, Gao B, Shepherd DC et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J. Clin. Invest. 103(11), 1509-1515 (1999).
32. Tahara N, Kai H, Niiyama H et al. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum. Gene Ther. 15(12), 1270-1278 (2004).
33. Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159(6), 1925-1932 (1999).
34. Bihari D, Smithies M, Gimson A, Tinker J. The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N. Engl. J. Med. 317(7), 397-403 (1987).
35. Kiernan FJ, Kluger J, Regnier JC, Rutkowski M, Fieldman A. Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction. Br. Heart J. 56(5), 428-432 (1986).
36. Ashby B. Comparison of Iloprost, Cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets. Prostaglandins 43(3), 255-261 (1992).
37. Moncada S, Gryglewski R, Bunting S, Vane Jr. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263(5579), 663-665 (1976).
38. Moncada S, Vane Jr. Prostacyclin and blood coagulation. Drugs 21(6), 430-437 (1981).
39. Flolan, package insert. GlaxoSmithKline, NC, USA.
40. Kingman MS, Tankersley MA, Lombardi S et al. Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. J. Heart Lung Transplant. 29(8), 841-846 (2010).
41. Kallen AJ, Lederman E, Balaji A et al. Bloodstream infections in patients given treatment with intravenous prostanoids.Infect. Control Hosp. Epidemiol. 29(4), 342-349 (2008).
42. Veletri®, package insert. Actelion Pharmaceuticals US Inc., CA, USA
43. Tyvaso®, package insert. United Therapeutics Corp., NC, USA.
44. Remodulin®, package insert. United Therapeutics Corp., NC, USA.
45. Tapson VF, Mclaughlin VV, Gomberg-Maitland M et al. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension. J. Vasc. Access 7(3), 112-117 (2006).
46. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J. Cardiovasc. Pharmacol. 44(2), 209-214 (2004).
47. Ventavis®, package insert. Actelion Pharmaceuticals US Inc., CA, USA.
48. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 334(5), 296-301 (1996).
49. Badesch DB, Tapson VF, Mcgoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132(6), 425-434 (2000).
50. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165(6), 800-804 (2002).
51. Hiremath J, Thanikachalam S, Parikh K et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J. Heart Lung Transplant. 29(2), 137-149 (2010).
52. Mclaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol. 55(18), 1915-1922 (2010).
53. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347(5), 322-329 (2002).
54. Mclaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174(11), 1257-1263 (2006).
55. Califf RM, Adams KF, Mckenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 134(1), 44-54 (1997).
56. Archer SL, Mike D, Crow J, Long W, Weir EK. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 109(3), 750-755 (1996).
57. Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 79(5), 377-382 (2010).
58. Minai OA, Sahoo D, Chapman JT, Mehta AC. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Resp. Med. 102(7), 1015-1020 (2008).
59. Cabrol S, Souza R, Jais X et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J. Heart Lung Transplant. 26(4), 357-362 (2007).
60. Skoro-Sajer N, Bonderman D, Wiesbauer F et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J. Thromb. Haemost. 5(3), 483-489 (2007).
61. Stitham J, Stojanovic A, Hwa J. Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J. Biol. Chem. 277(18), 15439-15444 (2002).
62. Fetalvero KM, Shyu M, Nomikos AP et al. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am. J. Physiol. 290(4), H1337-H1346 (2006).
63. Arehart E, Stitham J, Asselbergs FW et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ. Res. 102(8), 986-993 (2008).
64. Mohite A, Chillar A, So SP, Cervantes V, Ruan KH. Novel mechanism of the vascular protector prostacyclin: regulating microRNA expression. Biochemistry 50(10), 1691-1699 (2011).
65. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163), 411-415 (1988).
66. Penna C, Rastaldo R, Mancardi D et al. Effect of endothelins on the cardiovascular system. J. Cardiovasc. Med. 7(9), 645-652 (2006).
67. Khalil RA. Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension. Curr. Mol. Pharmacol. 4(3), 176-186 (2011).
68. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 61(2), 227-237 (2004).
69. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(Suppl. 12), S13-S24 (2004).
70. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43(15), 1089-1115 (2004).
71. van Giersbergen PL, Halabi A, Dingemanse J. Single-and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br. J. Clin. Pharmacol. 53(6), 589-595 (2002).
72. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Therapeut. 81(3), 414-419 (2007).
73. Dingemanse J, Schaarschmidt D, van Giersbergen PL. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin. Pharmacokinet. 42(3), 293-301 (2003).
74. Weber C, Schmitt R, Birnboeck H et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol. 39(7), 703-714 (1999).
75. Tracleer (bosentan) Risk Evaluation Mitigation Strategy (REMS). Actelion Pharmaceuticals US, Inc., CA, USA (2010).
76. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Disposit. 35(8), 1400-1407 (2007).
77. Letairis®, package insert. Gilead Sciences, Inc., CA, USA.
78. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002).
79. Galie N, Rubin L, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630), 2093-2100 (2008).
80. Galie N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23), 3010-3019 (2008).
81. Mcmurray JJ, Teerlink JR, Cotter G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298(17), 2009-2019 (2007).
82. Packer M, Mcmurray J, Massie BM et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Cardiac Fail. 11(1), 12-20 (2005).
83. Hefke T, Zittermann A, Fuchs U, Schulte-Eistrup S, Gummert JF, Schulz U. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac. Cardiovasc. Surg. 60(1), 26-34 (2012).
84. Stolz D, Rasch H, Linka A et al. A randomised, controlled trial of bosentan in severe COPD. Eur. Respir. J. 32(3), 619-628 (2008).
85. Gunther A, Enke B, Markart P et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur. Respir. J. 29(4), 713-719 (2007).
86. Badesch DB, Feldman J, Keogh A et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc. Therapeut. 30(2), 93-99 (2012).
87. Jais X, D'Armini AM, Jansa P et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension), a randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 52(25), 2127-2134 (2008).
88. Judson MA, Highland KB, Kwon S et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc. Diffuse Lung Dis. 28(2), 139-145 (2011).
89. Letairis® (ambrisentan) Risk Evaluation and Mitigation Strategy (REMS). Gilead Sciences, Inc., CA, USA (2012).
90. Gabler NB, French B, Strom BL et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141(1), 20-26 (2012).
91. Calabro P, Limongelli G, Maddaloni V et al. Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. Intern. Emerg. Med. 7(5), 425-430 (2012).
92. Weiss J, Herzog M, Haefeli WE. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur. J. Pharmacol. 660(2-3), 298-304 (2011).
93. Wharton J, Strange JW, Moller GM et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 172(1), 105-113 (2005).
94. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J. Clin. Pharmacol. 45(9), 987-1003 (2005).
95. Schermuly RT, Pullamsetti SS, Kwapiszewska G et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115(17), 2331-2339 (2007).
96. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol. 53(Suppl. 1), S5-S12 (2002).
97. Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br. J. Clin. Pharmacol. 53(Suppl. 1), S13-S20 (2002).
98. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. 50(2), 99-107 (2000).
99. Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br. J. Clin. Pharmacol. 53(Suppl. 1), S37-S43 (2002).
100. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. 60(1), 107-112 (2005).
101. Adcirca, package insert. Eli Lilly and Company, IN, USA.
102. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353(20), 2148-2157 (2005).
103. Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Int. Med. 149(8), 521-530 (2008).
104. Machado RF, Barst RJ, Yovetich NA et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 118(4), 855-864 (2011).
105. Galie N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22), 2894-2903 (2009).
106. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124(2), 164-174 (2011).
107. Reichenbach A, Al-Hiti H, Malek I et al. The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study. Int. J. Cardiol. pii: S0167-5273(12)01180-1 (2012).
108. Cooper TJ, Guazzi M, Al-Mohammad A et al. Sildenafil in Heart Failure (SILHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. Eur. J. Heart Fail. 15(1), 119-122 (2012).
109. Blanco I, Gimeno E, Munoz PA et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 181(3), 270-278 (2010).
110. Lederer DJ, Bartels MN, Schluger NW et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 9(3), 268-275 (2012).
111. Rietema H, Holverda S, Bogaard HJ et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur. Respir. J. 31(4), 759-764 (2008).
112. Holverda S, Rietema H, Bogaard HJ et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm. Pharmacol. Ther. 21(3), 558-564 (2008).
113. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131(3), 897-899 (2007).
114. Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360(9337), 895-900 (2002).
115. Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 30(5), 922-927 (2007).
116. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J. Heart Lung Transplant. 27(3), 329-334 (2008).
117. Revatio, package insert. Pfizer Labs, NY, USA.
118. Hazell L, Cornelius V, Wilton LV, Shakir SA. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients. BJU Int. 103(4), 506-514 (2009).
119. Margo CE, French DD. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. Am. J. Ophthalmol. 143(3), 538-539 (2007).
120. Salvi F, Sarzani R, Giorgi R et al. Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). Int. J. Impot. Res. 16(5), 412-417 (2004).
121. Peskircioglu L, Atac FB, Erdem SR, Deveci S, Verdi H, Ozkardes H. The association between intron 4 VNTR, E298A and IVF 23+10 G/T polymorphisms of ecNOS gene and sildenafil responsiveness in patients with erectile dysfunction. Int. J. Impot. Res. 19(2), 149-153 (2007).
122. Muniz JJ, Lacchini R, Rinaldi TO et al. Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction. Pharmacogenomics J. 13(2), 189-196 (2011).
123. Sperling H, Eisenhardt A, Virchow S et al. Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. J. Urol. 169(3), 1048-1051 (2003).
124. Jetter A, Lazar A, Schomig E, Fuhr U, Kinzig-Schippers M, Sorgel F. The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers. Clin. Pharmacol. Therapeutics 78(4), 441-443 (2005).
125. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327(2), 76-81 (1992).
126. Mclaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53(17), 1573-1619 (2009).
127. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23), 3105-3111 (2005).
128. Carlin CM, Celnik DF, Pak O, Wadsworth R, Peacock AJ, Welsh DJ. Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. Am. J. Resp. Cell Mol. Biol. 47(2), 140-148 (2012).
129. Ali OF, Growcott EJ, Butrous GS, Wharton J. Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Resp. Res. 12, 137 (2011).
130. Kawut SM, Bagiella E, Lederer DJ et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 123(25), 2985-2993 (2011).
131. Cavasin MA, Demos-Davies K, Horn TR et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ. Res. 110(5), 739-748 (2012).
132. Zhao L, Chen CN, Hajji N et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126(4), 455-467 (2012).
133. Bogaard HJ, Mizuno S, Hussaini AA et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am. J. Respir. Crit. Care Med. 183(10), 1402-1410 (2011).
134. Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int. Heart J. 51(4), 272-276 (2010).
135. Duggan N, Bonneau O, Hussey M et al. Comparison of effects of imatinib and nilotinib in a rodent model of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 181, A6304 (2010).
136. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 114(Suppl. 3), S225-S230 (1998).
137. Gomberg-Maitland M, Maitland ML, Barst RJ et al. A dosing/cross- development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.Clin. Pharmacol. Therapeut. 87(3), 303-310 (2010).
138. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353(13), 1412-1413 (2005).
139. Ghofrani HA, Morrell NW, Hoeper MM et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182(9), 1171-1177 (2010).
140. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann. Intern. Med. 145(2), 152-153 (2006).
141. Hoeper M, Barst R, Galie N et al. Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES). Presented at: European Repiratory Soceity Amsterdam 2011 Annual Congress. Amsterdam, The Netherlands, 24-28 September 2011 (Abstract 413).
142. Kawut SM, Horn EM, Berekashvili KK et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm. Pharmacol. Therapeut. 19(5), 370-374 (2006).
143. Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 136(3), 694-700 (2009).
144. de Man FS, Tu L, Handoko ML et al. Dysregulated renin-angiotensin- aldosterone system contributes to pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186(8), 780-789 (2012).
145. Rubin L, Pulido T, Channick R et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN Trial. Chest 142, A1026-A1026 (2012).
146. Tapson VF, Torres F, Kermeen F et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 142(6), 1383-1390 (2012).
147. Simonneau G, Lang I, Torbicki A et al. Efficacy, safety and tolerability of ACT 293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a Phase IIa study in pulmonary arterial hypertension (PAH). Am. J. Respir. Crit. Care Med. 181, A2515 (2010).
148. Hoeper MM, Halank M, Wilkens H et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur. Respir. J. 41(4), 853-860 (2013).
149. Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a Phase II study. Eur. Respir. J. 36(4), 792-799 (2010).
150. Kojonazarov B, Myrzaakhmatova A, Sooronbaev T, Ishizaki T, Aldashev A. Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur. Respir. J. 39(2), 496-498 (2012).
151. Fujita H, Fukumoto Y, Saji K et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25(2), 144-149 (2010).
152. Robbins IM, Hemnes AR, Gibbs JS et al. Safety of sapropterin dihydrochloride (6r bh4) in patients with pulmonary hypertension. Exp. Lung Res. 37(1), 26-34 (2011).
153. Dumitrascu R, Kulcke C, Konigshoff M et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur. Respir. J. 37(5), 1104-1118 (2011).
154. Dromparis P, Paulin R, Stenson TH, Haromy A, Sutendra G, Michelakis ED. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation 127(1), 115-125 (2013).
155. Li J, Long C, Cui W, Wang H. Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. J. Cardiovasc. Pharmacol. Therapeut. 18(1), 60-69 (2013).
156. Perez-Vizcaino F, Cogolludo A, Moreno L. Reactive oxygen species signaling in pulmonary vascular smooth muscle. Resp. Physiol. Neurobiol. 174(3), 212-220 (2010).
157. Ward JP, Mcmurtry IF. Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr. Opin. Pharmacol. 9(3), 287-296 (2009).
158. Kanki-Horimoto S, Horimoto H, Mieno S et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114(Suppl. 1), I181-I185 (2006).
159. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur. Respir. J. 39(2), 329-343 (2012).
160. Kataoka M, Kawakami T, Tamura Y et al. Gene transfer therapy by either type 1 or type 2 adeno-associated virus expressing human prostaglandin i2 synthase gene is effective for treatment of pulmonary arterial hypertension. J. Cardiovasc. Pharmacol. Therapeut. 18(1), 54-59 (2013).
161. Morecroft I, White K, Caruso P et al. Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension. Mol. Ther. 20(8), 1516-1528 (2012).
162. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991).
163. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH). http://clinicaltrials.gov/ ct2/show/NCT01179737
164. United Therapeutics Corportation. UT-15C treprostinil diethanolamine sustained release tablets (oral treprostinil). www.unither.com/oral- treprostinil-for-pah
165. A multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of beraprost sodium modified release in PAH patients. http://clinicaltrials.gov/ct2/show/NCT00781885 United Therapeutics Corportation. BPS for PAH. www.unither.com/bps-for-pah
166. ACT-293987 in pulmonary arterial hypertension. http://clinicaltrials.gov/ ct2/show/NCT011060146R-BH4 pulmonary arterial hypertension study. www.clinicaltrials.gov/ct2/show/NCT00435331.